Int'l App. No.: PCT/GB99/03280
Int'l Filing Date: 5 October 1999

REMARKS

The above-identified application is being entered into the National Phase from PCT application no. PCT/GB99/03280.

Applicants have amended the claims to put them in conformity with the U.S. practice.

Attached hereto is a marked-up version of the changes made to the specification and claims by the current amendment. The attached page is captioned "**Version with markings to show changes made.**"

No new matter has been introduced.

Respectfully submitted,

Yuriy P. Stercho, Ph.D.
Attorney for Applicants
Registration No. 33,797

SMITHKLINE BEECHAM CORPORATION
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, PA 19406-0939
Phone (610) 270-5018
Facsimile (610) 270-5090
n\yps\response\P32152\preamend

Int'l App. No.: PCT/GB99/03280
Int'l Filing Date: 5 October 1999

VERSION WITH MARKINGS TO SHOW CHANGES MADE

In the claims:

2. (Amended) A compound of formula (IB),



(IB)

or a derivative thereof, wherein:

R is hydrogen, alkyl, aryl, or aralkyl;

R^1 is hydrogen, alkyl, aralkyl, hydroxyalkyl or alkoxyalkyl;

R^2 is substituted or unsubstituted aryl or substituted or unsubstituted heterocyclyl;

R^3 is hydrogen, substituted or unsubstituted alkyl, cycloalkyl, alkoxyalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl or aralkyl wherein the aryl moiety is substituted or unsubstituted; or,

R^1 and R^3 together with the nitrogen to which they are attached form a single or fused, optionally substituted, saturated or unsaturated heterocylic ring;

with the proviso that formula (IB) does not include the following compounds [contained in List B]:

3-(4-methylpiperazin-l-yl)-4-phenyl-pyrrole-2,5-dione;
3-(4-ethylpiperazin-l-yl)-4-phenyl-pyrrole-2,5-dione;
3-(4-chlorophenyl)-4-(4-methyl-piperazin-l-yl)-pyrrole-2,5-dione;
3-[4-(diphenylmethyl)-1-piperazinyl]-4-(1H-indol-3-yl)-1-methyl-1H-pyrrole-2,5-dione;
3-phenyl-4-(4-methylpiperazino)-pyrrole-2,5-dione;
3-phenyl-4-(4-phenylpiperazino)-pyrrole-2,5-dione;
1-methyl-3-phenyl-4-(4-phenylpiperazino)-pyrrole-2,5-dione;
1-ethyl-3-phenyl-4-(4-chlorophenylpiperazino)-pyrrole-2,5-dione;
1-allyl-3-phenyl-4-(4-methylpiperazino)-pyrrole-2,5-dione;
3-phenylamino-4-phenyl-1H-pyrrole-2,5-dione;
3-phenyl-4-piperidin-1-yl-pyrrole-2,5-dione;
3-(3,5-dimethyl-1-phenyl-1H-pyrazol-4-yl)-4-morpholin-4-yl-pyrrole-2,5-dione;
3-indol-1-yl-4-(1-methyl-1H-indol-3-yl)-pyrrole-2,5-dione;
1-(1-methyl-2,5-dioxo-4-phenylamino-2,5-dihydro-1H-pyrrol-3-yl)-pyridinium chloride;
1-1-(4-methyl-pentyl)-2,5-dioxo-4-phenylamino-2,5-dihydro-1H-pyrrol-3-yl)-pyridinium chloride;
1-(1-dodecyl-2,5-dioxo-4-phenylamino-2,5-dihydro-1H-pyrrol-3-yl)-pyridinium chloride;

Int'l App. No.: PCT/GB99/03280
Int'l Filing Date: 5 October 1999

3-[2,5-dihydro-4-(1H-imidazol-1-yl)-1-methyl-2,5-dioxo-1H-pyrrol-3-yl]-1H-indole-1-carboxylic acid, 1,1-dimethylethyl ester;
3-[2-benzo[b]thien-2-yl-3-[4-(dimethylamino)-2,5-dihydro-2,5-dioxo-1H-pyrrol-3-yl]-1H-indol-1-yl]-carbamimidothioic acid, propyl ester;
3-(dimethylamino)-4-(1H-indol-3-yl)-1-methyl-1H-pyrrole-2,5-dione;
3-(1H-indol-3-yl)-1-methyl-4-(phenylamino)-1H-pyrrole-2,5-dione;
3-(1H-indol-3-yl)-1-methyl-4-[[4-(trifluoromethyl)phenyl]amino]-1H-pyrrole-2,5-dione;
3-(1H-indol-3-yl)-1-methyl-4-(methylamino)-1H-pyrrole-2,5-dione;
3-(1H-imidazo[4,5-b]pyridin-l-yl)-4-(1H-indol-3-yl)-1-methyl-1H-pyrrole-2,5-dione;
3-(6-chloro-9H-purin-9-yl)-4-(1H-indol-3-yl)-1-methyl-1H-pyrrole-2,5-dione;
3-(6-amino-9H-purin-9-yl)-4-(1H-indol-3-yl)-1-methyl-1H-pyrrole-2,5-dione;
3-(1H-indol-3-yl)-1-methyl-4-(1H-pyrrolo[2,3-b]pyridin-1-yl)-1H-pyrrole-2,5-dione;
3-(1H-indol-3-yl)-1-methyl-4-(1-piperidinyl)-1H-pyrrole-2,5-dione;
1-acetyl-3-[2,5-dihydro-1-methyl-2,5-dioxo-4-[[4-(trifluoromethyl)phenyl]amino]-1H-pyrrol-3-yl]-1H-indole;
3-(1H-benzimidazol-1-yl)-4-(1H-indol-3-yl)-1-methyl-1H-pyrrole-2,5-dione;
3-(1H-benzotriazol-1-yl)-4-(1H-indol-3-yl)-1-methyl-1H-pyrrole-2,5-dione;
3-(1H-imidazol-1-yl)-4-(1H-indol-3-yl)-1-methyl-1H-pyrrole-2,5-dione;
3-(1H-indol-1-yl)-4-(1H-indol-3-yl)-1-methyl-1H-pyrrole-2,5-dione;
3-(1H-indazol-1-yl)-4-(1H-indol-3-yl)-1-methyl-1H-pyrrole-2,5-dione;
3-[3-[(dimethylamino)methyl]-1H-indol-1-yl]-4-(1H-indol-3-yl)-1-methyl-1H-pyrrole-2,5-dione;
3-(1H-benzimidazol-1-yl)-4-(1H-indol-3-yl)-1H-pyrrole-2,5-dione;
3-(1H-indol-1-yl)-4-(1-methyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione;
3-(3,5-dimethyl-1-phenyl-1H-pyrazol-4-yl)-4-(4-morpholinyl)-1H-pyrrole-2,5-dione;
3-amino-4-(1H-indol-3-yl)-1H-pyrrole-2,5-dione;
3-amino-4-(5-methoxy-1H-indol-3-yl)-1H-pyrrole-2,5-dione;
1H-Indole-1-carboxylic acid, 3-(4-amino-2,5-dihydro-1-methyl-2,5-dioxo-1H-pyrrol-3-yl)-, 1,1-dimethylethyl ester ;
3-(1H-indol-3-yl)-1-methyl-4-[(phenylmethyl)amino]-1H-pyrrole-2,5-dione;
Glycine, N-[2,5-dihydro-4-(1H-indol-3-yl)-1-methyl-2,5-dioxo-1H-pyrrol-3-yl]-, ethyl ester ;
3-amino-4-(1H-indol-3-yl)-1-methyl-1H-pyrrole-2,5-dione;
1-(4-methylphenyl)-3-[(4-methylphenyl)amino]-4-phenyl-1H-pyrrole-2,5-dione ;
3-[[3-[(3-aminopropyl)amino]propyl]amino]-4-(1H-indol-3-yl)-1H-pyrrole-2,5-dione ;
3-[[3-[4-(3-aminopropyl)-1-piperazinyl]propyl]amino]-4-(1H-indol-3-yl)-1H-pyrrole-2,5-dione;
3-(1H-indol-3-yl)-4-[[3-(4-methyl-1-piperazinyl)propyl]amino]-1H-pyrrole-2,5-dione ;
1-[3-[(3-aminopropyl)amino]propyl]-3-[[3-[(3-aminopropyl)amino]propyl]amino]-4-(1H-indol-3-yl)-1H-pyrrole-2,5-dione;
1-[3-[4-(3-aminopropyl)-1-piperazinyl]propyl]-3-[[3-[4-(3-aminopropyl)-1-piperazinyl]propyl]amino]-4-(1H-indol-3-yl)-1H-pyrrole-2,5-dione;
3-(1H-indol-3-yl)-1-[3-(4-methyl-1-piperazinyl)propyl]-4-[[3-(4-methyl-1-piperazinyl)propyl]amino]-1H-pyrrole-2,5-dione;
3,3'-[iminobis(3,1-propanediylimino)]bis[4-(1H-indol-3-yl)-1H-pyrrole-2,5-dione;

Int'l App. No.: PCT/GB99/03280
Int'l Filing Date: 5 October 1999

3,3'-[1,4-piperazinediylbis(3,1-propanediylimino)]bis[4-(1H-indol-3-yl)-1H-pyrrole-2,5-dione;
3-amino-4-(3,4-dimethoxyphenyl)-1H-pyrrole-2,5-dione ;
3-[(5-aminopentyl)amino]-4-(1H-indol-3-yl)-1H-pyrrole-2,5-dione;
3-[[5-[(2-aminoethyl)amino]pentyl]amino]-4-(1H-indol-3-yl)-1H-pyrrole-2,5-dione;
3-[(2-aminoethyl)amino]-4-(1H-indol-3-yl)-1H-pyrrole-2,5-dione;
3-[(6-aminohexyl)amino]-4-(1H-indol-3-yl)-1H-pyrrole-2,5-dione ;
3-[(7-aminoheptyl)amino]-4-(1H-indol-3-yl)-1H-pyrrole-2,5-dione;
3-[[2-[(2-aminoethyl)amino]ethyl]amino]-4-(1H-indol-3-yl)-1H-pyrrole-2,5-dione;
Benzenepropanamide, .alpha.-amino-N-[5-[[2,5-dihydro-4-(1H-indol-3-yl)-2,5- dioxo-1H-pyrrol-3-yl]amino]pentyl]-, (S)- ;
Pentanoic acid, 4-amino-5-[[5-[[2,5-dihydro-4-(1H-indol-3-yl)-2,5-dioxo-1H-pyrrol-3-yl]amino]pentyl]amino]-5-oxo-, (S)- ;
Pentanamide, 2-amino-5-[(aminoiminomethyl)amino]-N-[2-[[5-[[2,5-dihydro-4-(1H-indol-3-yl)-2,5-dioxo-1H-pyrrol-3-yl]amino]pentyl]amino]ethyl]-, (S)-;
Benzenepropanamide, .alpha.-amino-N-[2-[[5-[[2,5-dihydro-4-(1H-indol-3-yl)-2,5-dioxo-1H-pyrrol-3-yl]amino]pentyl]amino]ethyl]-, (S)- ;
Butanamide, 4-[(aminoiminomethyl)amino]-N-[5-[[2,5-dihydro-4-(1H-indol-3-yl)-2,5-dioxo-1H-pyrrol-3-yl]amino]pentyl]-, (S)- ;
3-(4-methylphenyl)-1-phenyl-4-(phenylamino)-1H-pyrrole-2,5-dione;
1,3-bis(4-methylphenyl)-4-[(4-methylphenyl)amino]-1H-pyrrole-2,5-dione;p
3-amino-1,4-diphenyl-1H-pyrrole-2,5-dione;
3-(4-methylphenyl)-4-(4-morpholinyl)-1-phenyl-1H-pyrrole-2,5-dione ;
3-(4-methylphenyl)-1-phenyl-4-[(phenylmethyl)amino]-1H-pyrrole-2,5-dione;
3-amino-4-(4-methylphenyl)-1-phenyl-1H-pyrrole-2,5-dione ;
3-(3,5-dimethyl-1-phenyl-1H-pyrazol-4-yl)-4-(4-morpholinyl)-1H-pyrrole-2,5-dione;
3-(4-nitrophenyl)-1-phenyl-4-phenylamino-1H-pyrrole-2,5-dione ;
3-amino-1-methyl-4-p-tolyl-1H-pyrrole-2,5-dione;
3-(2-diethylamino-ethylamino)-4-phenyl-pyrrole-2,5-dione;
3-[butyl-(2-diethylamino-ethyl)-amino]-4-phenyl-pyrrole-2,5-dione;
3-[benzyl-(2-dimethylamino-ethyl)-amino]-4-phenyl-pyrrole-2,5-dione;
3-[benzyl-(2-dimethylamino-ethyl)-amino]-1-methyl-4-phenyl-pyrrole-2,5-dione;
3-[benzyl-(2-dimethylamino-ethyl)-amino]-4-(4-chloro-phenyl)-pyrrole-2,5-dione;
3-[benzyl-(2-diethylamino-ethyl)-amino]-4-phenyl-pyrrole-2,5-dione;
3-[benzyl-(2-dimethylamino-ethyl)-amino]-4-(3-methoxy-phenyl)-pyrrole-2,5-dione;
3-(4-chloro-phenyl)-4-[2-(4-methyl-piperazin-1-yl)-ethylamino]-pyrrole-2,5-dione;
3-[2-(4-methyl-piperazin-1-yl)-ethylamino]-4-phenyl-pyrrole-2,5-dione;
3-phenyl-4-(diethylamino)-pyrrole-2,5-dione;
3-phenyl-4-(benzylamino)-pyrrole-2,5-dione;
1-methyl-3-phenyl-4-(2-diethylaminoethylamino)-pyrrole-2,5-dione;
1-allyl-3-phenyl-4-(2-dimethylaminoethylamino)-pyrrole-2,5-dione; and;
1,3-diphenyl-4-piperidino-pyrrole-2,5-dione.

Int'l App. No.: PCT/GB99/03280
Int'l Filing Date: 5 October 1999

3. (Amended) A compound according to claim 2 of formula (IC')



(IC')

wherein;

R is hydrogen, alkyl, aryl or aralkyl;

R' is hydrogen, alkyl, aralkyl, hydroxyalkyl or alkoxyalkyl;

[R and R^1 are as defined in relation to formula (I) in claim 1;]

R^{10} represents hydrogen or one or more substituents, suitably up to three, selected from the group [list] consisting of: alkoxycarbonyl, alkoxyalkyl, perfluoroalkyl, perfluoroalkylS-, perfluoroalkylO-, phenyl(di-C_{1-6}alkoxy)C-, benzoyl, C_{1-6}alkylSO$_2$-, -[(CH=CH)$_2$]-, phenyl, nitro, -OCH$_2$O-, benzyloxy, phenoxy, halo, hydroxy, alkyl, alkoxy, amino, mono- or di-alkyl amino and [or] thioalkyl;

R^{11} represents hydrogen or one or more substituents, suitably up to three, selected from the group [list] consisting of: substituted or unsubstituted C_{1-6}alkyl, phenyl, benzyl, substituted or unsubstituted C_{1-6}alkylS-, halo, hydroxy, substituted or unsubstituted C_{1-6}alkoxy, substituted or unsubstituted phenoxy, indolyl, naphthyl, carboxy, C_{1-6}alkoxycarbonyl, benzyloxy, phenoxy, pentafluorophenoxy, nitro, substituted or unsubstituted carbamoyl, substituted or unsubstituted C_{1-6}alkylcarbonyl, benzoyl, cyano, perfluoroC_{1-6}alkylSO$_2$-, C_{1-6}alkylNHSO$_2$-, oxazolyl, substituted or unsubstituted phenylS-, C_{1-6}alkylpiperazinyl-, C_{1-6}alkylcarbonylpiperazinyl-, 1,2,3-thiadiazolyl, pyrimidin-2-yloxy, N-[pyrimidin-2-yl]-N-methylamino, phenylamino, C_{1-6}alkylsulphonylamino, N-morpholinylcarbonyl, cyclohexyl, adamantyl, trityl, substituted or unsubstituted C_{1-6}alkenyl, perfluoroC_{1-6}alkyl, perfluoroC_{1-6}alkoxy, perfluoroC_{1-6}alkylS-, aminosulphonyl, morpholino, (diC_{1-6}alkyl)amino, C_{1-6}alkylCONH-, (diC_{1-6}alkoxy)phenyl(CH$_2$)$_n$NHC(O)CH(phenyl)S- where n is 1 to 6, and C_{1-6}alkylCON(C_{1-6}alkyl)-, thiazolidinedionylC_{1-6}alkyl, phenylCH(OH)-, substituted or unsubstituted piperazinylC_{1-6}alkoxy, substituted or unsubstituted benzoylamino;
or -(CH$_2$)$_x$-, -SCH=N-, -SC(C_{1-6}alkyl)=N-, -OCF$_2$O-, -[CH=CHC(O)O]-, -[N=CH-CH=CH]-, -CH=N-NH-, -CH=CH-NH-, -OC(NHC_{1-6}alkyl)=N-, -OC(O)NH-, -C(O)NMeC(O)-, -C(O)NHC(O)-, -(CH$_2$)$_x$C(O)-, -N=N-NH-, -N=C(C_{1-6}alkyl)O-, -O(CH$_2$)$_x$O-, -(CH$_2$)$_x$SO$_2$(CH$_2$)$_y$-, and -N(C_{1-6}alkylcarbonyl)(CH$_2$)$_x$-, where x and y are independently 1 to 4;
with the proviso that (IC') does not include:
3-phenylamino-4-phenyl-1H-pyrrole-2,5-dione;
1-(4-methylphenyl)-3-[(4-methylphenyl)amino]-4-phenyl-1H-pyrrole-2,5-dione;
3-(4-methylphenyl)-1-phenyl-4-(phenylamino)-1H-pyrrole-2,5-dione;
1,3-bis(4-methylphenyl)-4-[(4-methylphenyl)amino]-1H-yrrole-2,5-dione, or;
3-(4-nitrophenyl)-1-phenyl-4-phenylamino-1H-pyrrole-2,5-dione.

Int'l App. No.: PCT/GB99/03280
Int'l Filing Date: 5 October 1999

5. (Amended) A compound according to claim 2 of formula (ID')



(ID')

wherein

R is hydrogen, alkyl, aryl or aralkyl;

R' is hydrogen, alkyl, aralkyl, hydroxyalkyl or alkoxyalkyl;

[R and R^1 are as defined in relation to formula (I) in claim 1]

$R^{2'}$ is phenyl, substituted phenyl or indolyl;

$R^{3'}$ is hydrogen, alkyl, cycloalkyl, phenyl, substituted phenyl, C_{1-6} alkylphenyl wherein the phenyl group is optionally substituted, alkoxyalkyl, substituted or unsubstituted heterocyclyl, with the proviso that formula (ID') does not include the following compounds [contained in List D']:.

3-[2-benzo[b]thien-2-yl-3-[4-(dimethylamino)-2,5-dihydro-2,5-dioxo-1H-pyrrol-3-yl]-1H-indol-1-yl]-carbamimidothioic acid,propyl ester;
3-(dimethylamino)-4-(1H-indol-3-yl)-1-methyl-1H-pyrrole-2,5-dione;
3-(1H-indol-3-yl)-1-methyl-4-(phenylamino)-1H-pyrrole-2,5-dione;
3-(1H-indol-3-yl)-1-methyl-4-[[4-(trifluoromethyl)phenyl]amino]-1H-pyrrole-2,5-dione;
3-(1H-indol-3-yl)-1-methyl-4-(methylamino)-1H-pyrrole-2,5-dione;
3-(6-chloro-9H-purin-9-yl)-4-(1H-indol-3-yl)-1-methyl-1H-pyrrole-2,5-dione;
3-(6-amino-9H-purin-9-yl)-4-(1H-indol-3-yl)-1-methyl-1H-pyrrole-2,5-dione;
1-acetyl-3-[2,5-dihydro-1-methyl-2,5-dioxo-4-[[4-(trifluoromethyl)phenyl]amino]-1H-pyrrol-3-yl]-1H-indole;
3-amino-4-(1H-indol-3-yl)-1H-pyrrole-2,5-dione;
3-amino-4-(5-methoxy-1H-indol-3-yl)- 1H-pyrrole-2,5-dione;
1H-Indole-1-carboxylic acid, 3-(4-amino-2,5-dihydro-1-methyl-2,5-dioxo-1H-pyrrol-3-yl)-, 1,1-dimethylethyl ester;
3-(1H-indol-3-yl)-1-methyl-4-[(phenylmethyl)amino]-1H-pyrrole-2,5-dione;
Glycine, N-[2,5-dihydro-4-(1H-indol-3-yl)-1-methyl-2,5-dioxo-1H-pyrrol-3-yl]-, ethyl ester;
3-amino-4-(1H-indol-3-yl)-1-methyl-1H-pyrrole-2,5-dione;
3-[[3-[(3-aminopropyl)amino]propyl]amino]-4-(1H-indol-3-yl)-1H-pyrrole-2,5-dione;
3-[[3-[4-(3-aminopropyl)-1-piperazinyl]propyl]amino]-4-(1H-indol-3-yl)-1H-pyrrole-2,5-dione;
3-(1H-indol-3-yl)-4-[[3-(4-methyl-1-piperazinyl)propyl]amino]-1H-pyrrole-2,5-dione;
1-[3-[(3-aminopropyl)amino]propyl]-3-[[3-[(3-aminopropyl)amino]propyl]amino]-4-(1H-indol-3-yl)-1H-pyrrole-2,5-dione;

Int'l App. No.: PCT/GB99/03280
Int'l Filing Date: 5 October 1999

1-[3-[4-(3-aminopropyl)-1-piperazinyl]propyl]-3-[[3-[4-(3-aminopropyl)-1-piperazinyl]propyl]amino]-4-(1H-indol-3-yl)-1H-pyrrole-2,5-dione;
3-(1H-indol-3-yl)-1-[3-(4-methyl-1-piperazinyl)propyl]-4-[[3-(4-methyl-1-piperazinyl)propyl]amino]-1H-pyrrole-2,5-dione;
3,3'-[iminobis(3,1-propanediylimino)]bis[4-(1H-indol-3-yl)-1H-pyrrole-2,5-dione;
3,3'-[1,4-piperazinediylbis(3,1-propanediylimino)]bis[4-(1H-indol-3-yl)-1H-pyrrole-2,5-dione;
3-amino-4-(3,4-dimethoxyphenyl)-1H-pyrrole-2,5-dione;
3-[(5-aminopentyl)amino]-4-(1H-indol-3-yl)-1H-pyrrole-2,5-dione;
3-[[5-[(2-aminoethyl)amino]pentyl]amino]-4-(1H-indol-3-yl)-1H-pyrrole-2,5-dione;
3-[(2-aminoethyl)amino]-4-(1H-indol-3-yl)-1H-pyrrole-2,5-dione;
3-[(6-aminohexyl)amino]-4-(1H-indol-3-yl)-1H-pyrrole-2,5-dione;
3-[(7-aminoheptyl)amino]-4-(1H-indol-3-yl)-1H-pyrrole-2,5-dione;
3-[[2-[(2-aminoethyl)amino]ethyl]amino]-4-(1H-indol-3-yl)-1H-pyrrole-2,5-dione;
Benzenepropanamide, .alpha.-amino-N-[5-[[2,5-dihydro-4-(1H-indol-3-yl)-2,5- dioxo-1H-pyrrol-3-yl]amino]pentyl]-, (S)-;
Pentanoic acid, 4-amino-5-[[5-[[2,5-dihydro-4-(1H-indol-3-yl)-2,5-dioxo-1H-pyrrol-3-yl]amino]pentyl]amino]-5-oxo-, (S)-;
Pentanamide, 2-amino-5-[(aminoiminomethyl)amino]-N-[2-[[5-[[2,5-dihydro-4-(1H-indol-3-yl)-2,5-dioxo-1H-pyrrol-3-yl]amino]pentyl]amino]ethyl]-, (S)-;
Benzenepropanamide, .alpha.-amino-N-[2-[[5-[[2,5-dihydro-4-(1H-indol-3-yl)-2,5-dioxo-1H-pyrrol-3-yl]amino]pentyl]amino]ethyl]-, (S)-;
Butanamide, 4-[(aminoiminomethyl)amino]-N-[5-[[2,5-dihydro-4-(1H-indol-3-yl)-2,5-dioxo-1H-pyrrol-3-yl]amino]pentyl]-, (S)-;
3-amino-1,4-diphenyl-1H-pyrrole-2,5-dione;
3-(4-methylphenyl)-1-phenyl-4-[(phenylmethyl)amino]-1H-pyrrole-2,5-dione;
3-amino-4-(4-methylphenyl)-1-phenyl-1H-pyrrole-2,5-dione;
3-amino-1-methyl-4-p-tolyl-1H-pyrrole-2,5-dione;
3-(2-diethylamino-ethylamino)-4-phenyl-pyrrole-2,5-dione;
3-[butyl-(2-diethylamino-ethyl)-amino]-4-phenyl-pyrrole-2,5-dione;
3-[benzyl-(2-dimethylamino-ethyl)-amino]-4-phenyl-pyrrole-2,5-dione;
3-[benzyl-(2-dimethylamino-ethyl)-amino]-1-methyl-4-phenyl-pyrrole-2,5-dione;
3-[benzyl-(2-dimethylamino-ethyl)-amino]-4-(4-chloro-phenyl)-pyrrole-2,5-dione;
3-[benzyl-(2-diethylamino-ethyl)-amino]-4-phenyl-pyrrole-2,5-dione;
3-[benzyl-(2-dimethylamino-ethyl)-amino]-4-(3-methoxy-phenyl)-pyrrole-2,5-dione;
3-(4-chloro-phenyl)-4-[2-(4-methyl-piperazin-1-yl)-ethylamino]-pyrrole-2,5-dione;
3-[2-(4-methyl-piperazin-1-yl)-ethylamino]-4-phenyl-pyrrole-2,5-dione;
3-phenyl-4-(diethylamino)-pyrrole-2,5-dione;
3-phenyl-4-(benzylamino)-pyrrole-2,5-dione;
1-methyl-3-phenyl-4-(2-diethylaminoethylamino)-pyrrole-2,5-dione, and;
1-allyl-3-phenyl-4-(2-dimethylaminoethylamino)-pyrrole-2,5-dione.

6. (Amended) A compound according to claim 2 of formula (IE')

Int'l App. No.: PCT/GB99/03280
Int'l Filing Date: 5 October 1999



(IE')

wherein R is hydrogen, alkyl or aralkyl; [as defined in relation to formula (I) in claim 1;]

$R^{10'}$ represents hydrogen or one or more, suitably up to three, substituents selected from the group [list] consisting of: alkoxy, halo, and nitro;

P'-Q' represents $-(CH_2)_aO(CH_2)_b-$, $-(CH_2)_aS(CH_2)_b-$, $-(CH_2)_c-$, $-(CH_2)_dCH(G)(CH_2)_e-$, $-(CH_2)_aN(ZZ)(CH_2)_b-$,where a, b, d, and e are independently 1 to 4, c is 1 to 6, ZZ is hydrogen, alkyl, aryl, or alkylcarbonyl, and G is alkyl, amido, hydroxyalkyl, aralkyl, or hydroxy, with the proviso that (IE') does not include:

3-phenyl-4-piperidin-1-yl-pyrrole-2,5-dione;
3-(4-methylpiperazin-l-yl)-4-phenyl-pyrrole-2,5-dione;
3-(4-ethylpiperazin-l-yl)-4-phenyl-pyrrole-2,5-dione;
3-(4-chlorophenyl)-4-(4-methyl-piperazin-l-yl)-pyrrole-2,5-dione;
3-(4-methylphenyl)-4-(4-morpholinyl)-1-phenyl-1H-pyrrole-2,5-dione
3-phenyl-4-(4-methylpiperazino)-pyrrole-2,5-dione;
3-phenyl-4-(4-phenylpiperazino)-pyrrole-2,5-dione;
1-methyl-3-phenyl-4-(4-phenylpiperazino)-pyrrole-2,5-dione;
1-ethyl-3-phenyl-4-(4-chlorophenylpiperazino)-pyrrole-2,5-dione;
1-allyl-3-phenyl-4-(4-methylpiperazino)-pyrrole-2,5-dione, and;
1,3-diphenyl-4-piperidino-pyrrole-2,5-dione.

7. (Amended) A compound according to claim 2 of formula (IF)



(IF)

wherein R is hydrogen, alkyl or aralkyl; [as defined in relation to formula (I) in claim 1;]

Int'l App. No.: PCT/GB99/03280
Int'l Filing Date: 5 October 1999

R10" is one or more, suitably up to three, substituents selected from the group [list] consisting of perfluoroalkyl, halo, nitro, alkoxy, arylcarbonyl, and alkyl;

Z is a bond or an alkylene chain;

-X-Y- is –CH=N, $-(CH_2)_t-$, $-(CH_2)_uCH(U)-$, $-(U)CH(CH_2)_u-$, -CH=CH-, $-(CH_2)_vC(alkyl)_2-$, $-C(O)C(alkyl)_2-$, -C(O)O-, where t, u, and v are independently 1 to 4, and U is alkyl, carboxy, alkoxycarbonyl, hydroxyalkyl, and amido;

$R^{12a'}$, $R^{12b'}$, and $R^{12c'}$ are each independently hydrogen, nitro, alkoxy, 4-ethylpiperazin-1-yl, 4-BOC-piperazin-1-yl, 4-methyl-piperazin-1-yl, 4-methyl-piperazin-1-yl, halo, alkyl, piperazin-1-yl, perfluoroalkyl, and alkylsulphonylamino.

8. (Amended) A compound according to claim 2 of formula (IG)



(IG)

wherein

R is hydrogen, alkyl, aryl or aralkyl;

R' is hydrogen, alkyl, aralkyl, hydroxyalkyl or alkoxyalkyl;

[R and R^1 are as defined in relation to formula (I) in claim 1;]

A is N(alkyl), oxygen, or sulphur.

[Examples of A are N(methyl), oxygen, and sulphur.

Preferably, A is sulphur.]

$R^{11"}$ is one or more, suitably up to three, substituents selected from the group consisting of hydrogen, halo, alkyl, alkylthio, -S-CH=N-, phenoxy, $-(CH_2)_w-$, hydroxy, carboxy, $-O(CH_2)_xO-$, hydroxyalkyl, and alkylaminosulphonylalkyl, where w and x are independently 1 to 4.

9. (Amended) A compound according to claim 2 of formula (IH)



(IH)

Int'l App. No.: PCT/GB99/03280
Int'l Filing Date: 5 October 1999

wherein

R is hydrogen, alkyl, aryl or aralkyl;

R' is hydrogen, alkyl, aralkyl, hydroxyalkyl or alkoxyalkyl;

[R and R^1 are as defined in relation to formula (I) in claim 1;]

$R^{11'''}$ is $-[(CH_2)_{aa}]-$, where aa is 1 to 4;

$R^{14'}$ is hydrogen;

$R^{15'}$ is alkyl, unsubstituted or substituted phenylamino, unsubstituted or substituted phenylalkylamino, cyclohexylamino, alkenylamino, phenyl, benzyl, styryl, or alkylamino.

10. (Amended) A compound according to claim 2 of formula (IJ)



(IJ)

wherein

R is hydrogen, alkyl, aryl or aralkyl;

R' is hydrogen, alkyl, aralkyl, hydroxyalkyl or alkoxyalkyl;

[R and R^1 are as defined in relation to formula (I) in claim 1;]

$R^{10'''}$ represents one or more, suitably up to three, substituents independently selected from alkoxy or halo;

$R^{16'}$ represents one or more, suitably up to three, substituents independently selected from hydrogen, carboxy, alkoxycarbonyl, or alkylaminocarbonyl;

$R^{17'}$ represents one or more, suitably up to three, substituents independently selected from carboxy, alkoxycarbonyl, halo, alkylaminocarbonyl, nitro, or hydrogen;

W is sulphur, oxygen, or substituted or unsubstituted NH.

11. (Amended) A compound according to claim 2 of formula (IK)

Int'l App. No.: PCT/GB99/03280
Int'l Filing Date: 5 October 1999



(IK)

wherein

R is hydrogen, alkyl, aryl or aralkyl;

R' is hydrogen, alkyl, aralkyl, hydroxyalkyl or alkoxyalkyl;

[R and R^1 are as defined in relation to formula (I) in claim 1;]

$R^{11''''}$ represents one or more, suitably up to three, substituents independently selected from halo and hydroxy;

$R^{18'}$ represents one or more, suitably up to three, substituents independently selected from hydrogen, alkyl, and $-(CH=CH)_2-$;

A is sulphur.

12. (Amended) A compound according to claim 2 of formula (IL')



(IL')

wherein R is hydrogen, alkyl, aryl or aralkyl; [as defined in relation to formula (I) in claim 1;]

$R^{2'''}$ is unsubstituted or substituted heterocyclyl or unsubstituted or substituted aryl;

$R^{19'}$ is unsubstituted or substituted heterocyclyl, or a quaternised salt thereof, with the proviso that formula (IL') does not include the following compounds [contained in List L'.]:

3-indol-1-yl-4-(1-methyl-1H-indol-3-yl)-pyrrole-2,5-dione;
1-(1-methyl-2,5-dioxo-4-phenylamino-2,5-dihydro-1H-pyrrol-3-yl)-pyridinium chloride;
1-1-(4-methyl-pentyl)-2,5-dioxo-4-phenylamino-2,5-dihydro-1H-pyrrol-3-yl)-pyridinium chloride;
1-(1-dodecyl-2,5-dioxo-4-phenylamino-2,5-dihydro-1H-pyrrol-3-yl)-pyridinium chloride;
3-[2,5-dihydro-4-(1H-imidazol-1-yl)-1-methyl-2,5-dioxo-1H-pyrrol-3-yl]-1H-indole-1-carboxylic acid, 1,1-dimethylethyl ester;
3-(1H-imidazo[4,5-b]pyridin-l-yl)-4-(1H-indol-3-yl)-1-methyl-1H-pyrrole-2,5-dione;
3-(1H-indol-3-yl)-1-methyl-4-(1H-pyrrolo[2,3-b]pyridin-1-yl)-1H-pyrrole-2,5-dione;

Int'l App. No.: PCT/GB99/03280
Int'l Filing Date: 5 October 1999

3-(1H-indol-3-yl)-1-methyl-4-(1-piperidinyl)-1H-pyrrole-2,5-dione;
3-[4-(diphenylmethyl)-1-piperazinyl]-4-(1H-indol-3-yl)-1-methyl-1H-pyrrole-2,5-dione;
3-(1H-benzimidazol-1-yl)-4-(1H-indol-3-yl)-1-methyl-1H-pyrrole-2,5-dione;
3-(1H-benzotriazol-1-yl)-4-(1H-indol-3-yl)-1-methyl-1H-pyrrole-2,5-dione;
3-(1H-imidazol-1-yl)-4-(1H-indol-3-yl)-1-methyl-1H-pyrrole-2,5-dione;
3-(1H-indol-1-yl)-4-(1H-indol-3-yl)-1-methyl-1H-pyrrole-2,5-dione;
3-(1H-indazol-1-yl)-4-(1H-indol-3-yl)-1-methyl-1H-pyrrole-2,5-dione;
3-[3-[(dimethylamino)methyl]-1H-indol-1-yl]-4-(1H-indol-3-yl)-1-methyl-1H-pyrrole-2,5-dione;
3-(1H-benzimidazol-1-yl)-4-(1H-indol-3-yl)-1H-pyrrole-2,5-dione;
3-(1H-indol-1-yl)-4-(1-methyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione, and;
3-(3,5-dimethyl-1-phenyl-1H-pyrazol-4-yl)-4-(4-morpholinyl)-1H-pyrrole-2,5-dione.

13. (Amended) A process for the preparation of a compound of the invention which process comprises reaction of a compound of formula (II):



(II)

wherein

R is hydrogen, alkyl, aryl, or aralkyl;

R^2 is substituted or unsubstituted aryl or substituted or unsubstituted heterocyclyl;

[R and R^2 are as defined in formula (I) in claim 1] and L is a leaving group, with a compound of formula (III):



(III)

wherein

R^1 is hydrogen, alkyl, aralkyl, hydroxyalkyl or alkoxyalkyl;

R^3 is hydrogen, substituted or unsubstituted alkyl, cycloalkyl, alkoxyalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl or aralkyl wherein the aryl moiety is substituted or unsubstituted;

[R^1 and R^3 are as defined in formula (I) in claim 1;] and thereafter, if required, carrying out one or more of the following optional steps:

(i) converting a compound of formula (I) to a further compound of formula (I);

(ii) removing any necessary protecting group;

(iii) preparing an appropriate derivative of the compound so formed.

Int'l App. No.: PCT/GB99/03280
Int'l Filing Date: 5 October 1999

16. (Amended) A compound of formula (IA)



(IA)

wherein

R is hydrogen, alkyl, aryl, or aralkyl;

R^1 is hydrogen, alkyl, aralkyl, hydroxyalkyl or alkoxyalkyl;

R^2 is substituted or unsubstituted aryl or substituted or unsubstituted heterocyclyl;

R^3 is hydrogen, substituted or unsubstituted alkyl, cycloalkyl, alkoxyalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl or aralkyl wherein the aryl moiety is substituted or unsubstituted; or,

R^1 and R^3 together with the nitrogen to which they are attached form a single or fused, optionally substituted, saturated or unsaturated heterocylic ring;

or a pharmaceutically acceptable derivative thereof, for use as an active therapeutic substance, with the proviso that formula (IA) does not include the following compounds: [contained in List A.]

3-phenyl-4-(4-methylpiperazino)-pyrrole-2,5-dione;
3-[4-(diphenylmethyl)-1-piperazinyl]-4-(1H-indol-3-yl)-1-methyl-1H-pyrrole-2,5-dione;
3-phenyl-4-(4-phenylpiperazino)-pyrrole-2,5-dione;
1-methyl-3-phenyl-4-(4-phenylpiperazino)-pyrrole-2,5-dione;
1-ethyl-3-phenyl-4-(4-chlorophenylpiperazino)-pyrrole-2,5-dione;
1-allyl-3-phenyl-4-(4-methylpiperazino)-pyrrole-2,5-dione;
3-indol-1-yl-4-(1-methyl-1H-indol-3-yl)-pyrrole-2,5-dione;
1-(1-methyl-2,5-dioxo-4-phenylamino-2,5-dihydro-1H-pyrrol-3-yl)pyridinium chloride;
1-[1-(4-methyl-pentyl)-2,5-dioxo-4-phenylamino-2,5-dihydro-1H-pyrrol-3-yl]pyridinium chloride;
1-(1-dodecyl-2,5-dioxo-4-phenylamino-2,5-dihydro-1H-pyrrol-3-yl)-pyridinium chloride;
3-[2-benzo[b]thien-2-yl-3-[4-(dimethylamino)-2,5-dihydro-2,5-dioxo-1H-pyrrol-3-yl]-1H-indol-1-yl]-carbamimidothioic acid, propyl ester;
3-(dimethylamino)-4-(1H-indol-3-yl)-1-methyl-1H-pyrrole-2,5-dione;
3-(1H-indol-3-yl)-1-methyl-4-(phenylamino)-1H-pyrrole-2,5-dione;
3-(1H-indol-3-yl)-1-methyl-4-[[4-(trifluoromethyl)phenyl]amino]-1H-pyrrole-2,5-dione;
3-(1H-indol-3-yl)-1-methyl-4-(methylamino)-1H-pyrrole-2,5-dione;
3-(1H-imidazo[4,5-b]pyridin-1-yl)-4-(1H-indol-3-yl)-1-methyl-1H-pyrrole-2,5-dione;
3-(6-chloro-9H-purin-9-yl)-4-(1H-indol-3-yl)-1-methyl-1H-pyrrole-2,5-dione;
3-(6-amino-9H-purin-9-yl)-4-(1H-indol-3-yl)-1-methyl-1H-pyrrole-2,5-dione;
3-(1H-indol-3-yl)-1-methyl-4-(1H-pyrrolo[2,3-b]pyridin-1-yl)-1H-pyrrole-2,5-dione;
3-(1H-indol-3-yl)-1-methyl-4-(1-piperidinyl)-1H-pyrrole-2,5-dione;

Int'l App. No.: PCT/GB99/03280
Int'l Filing Date: 5 October 1999

1-acetyl-3-[2,5-dihydro-1-methyl-2,5-dioxo-4-[[4-(trifluoromethyl)phenyl]amino]-1H-pyrrol-3-yl]-1H-indole;
3-(1H-benzimidazol-1-yl)-4-(1H-indol-3-yl)-1-methyl-1H-pyrrole-2,5-dione;
3-(1H-benzotriazol-1-yl)-4-(1H-indol-3-yl)-1-methyl-1H-pyrrole-2,5-dione;
3-(1H-imidazol-1-yl)-4-(1H-indol-3-yl)-1-methyl-1H-pyrrole-2,5-dione;
3-(1H-indol-1-yl)-4-(1H-indol-3-yl)-1-methyl-1H-pyrrole-2,5-dione;
3-(1H-indazol-1-yl)-4-(1H-indol-3-yl)-1-methyl-1H-pyrrole-2,5-dione;
3-[3-[(dimethylamino)methyl]-1H-indol-1-yl]-4-(1H-indol-3-yl)-1-methyl-1H-pyrrole-2,5-dione;
3-(1H-benzimidazol-1-yl)-4-(1H-indol-3-yl)-1H-pyrrole-2,5-dione;
3-(1H-indol-1-yl)-4-(1-methyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione;
3-amino-4-(1H-indol-3-yl)-1H-pyrrole-2,5-dione;
3-amino-4-(5-methoxy-1H-indol-3-yl)-1H-pyrrole-2,5-dione;
1H-Indole-1-carboxylic acid, 3-(4-amino-2,5-dihydro-1-methyl-2,5-dioxo-1H-pyrrol-3-yl)-, 1,1-dimethylethyl ester ;
3-(1H-indol-3-yl)-1-methyl-4-[(phenylmethyl)amino]-1H-pyrrole-2,5-dione;
Glycine, N-[2,5-dihydro-4-(1H-indol-3-yl)-1-methyl-2,5-dioxo-1H-pyrrol-3-yl]-, ethyl ester ;
3-amino-4-(1H-indol-3-yl)-1-methyl-1H-pyrrole-2,5-dione;
3-[[3-[(3-aminopropyl)amino]propyl]amino]-4-(1H-indol-3-yl)-1H-pyrrole-2,5-dione;
[[3-[4-(3-aminopropyl)-1-piperazinyl]propyl]amino]-4-(1H-indol-3-yl)-1H-pyrrole-2,5-dione;
3-(1H-indol-3-yl)-4-[[3-(4-methyl-1-piperazinyl)propyl]amino]-1H-pyrrole-2,5-dione ;
1-[3-[(3-aminopropyl)amino]propyl]-3-[[3-[(3-aminopropyl)amino]propyl]amino]-4-(1H-indol-3-yl)-1H-pyrrole-2,5-dione;
1-[3-[4-(3-aminopropyl)-1-piperazinyl]propyl]-3-[[3-[4-(3-aminopropyl)-1-piperazinyl]propyl]amino]-4-(1H-indol-3-yl)-1H-pyrrole-2,5-dione;
3-(1H-indol-3-yl)-1-[3-(4-methyl-1-piperazinyl)propyl]-4-[[3-(4-methyl-1-piperazinyl)propyl]amino]-1H-pyrrole-2,5-dione;
3,3'-[iminobis(3,1-propanediylimino)]bis[4-(1H-indol-3-yl)-1H-pyrrole-2,5-dione;
3,3'-[1,4-piperazinediylbis(3,1-propanediylimino)]bis[4-(1H-indol-3-yl)-1H-pyrrole-2,5-dione;
3-[(5-aminopentyl)amino]-4-(1H-indol-3-yl)-1H-pyrrole-2,5-dione;
3-[[5-[(2-aminoethyl)amino]pentyl]amino]-4-(1H-indol-3-yl)-1H-pyrrole-2,5-dione;
3-[(2-aminoethyl)amino]-4-(1H-indol-3-yl)-1H-pyrrole-2,5-dione ;
3-[(6-aminohexyl)amino]-4-(1H-indol-3-yl)-1H-pyrrole-2,5-dione ;
3-[(7-aminoheptyl)amino]-4-(1H-indol-3-yl)-1H-pyrrole-2,5-dione;
3-[[2-[(2-aminoethyl)amino]ethyl]amino]-4-(1H-indol-3-yl)-1H-pyrrole-2,5-dione;
Benzenepropanamide, .alpha.-amino-N-[5-[[2,5-dihydro-4-(1H-indol-3-yl)-2,5- dioxo-1H-pyrrol-3-yl]amino]pentyl]-, (S)- ;
Pentanoic acid, 4-amino-5-[[5-[[2,5-dihydro-4-(1H-indol-3-yl)-2,5-dioxo-1H-pyrrol-3-yl]amino]pentyl]amino]-5-oxo-, (S)- ;
Pentanamide, 2-amino-5-[(aminoiminomethyl)amino]-N-[2-[[5-[[2,5-dihydro-4-(1H-indol-3-yl)-2,5-dioxo-1H-pyrrol-3-yl]amino]pentyl]amino]ethyl]-, (S)-;
Benzenepropanamide, .alpha.-amino-N-[2-[[5-[[2,5-dihydro-4-(1H-indol-3-yl)-2,5-dioxo-1H-pyrrol-3-yl]amino]pentyl]amino]ethyl]-, (S)- ;

Int'l App. No.: PCT/GB99/03280
Int'l Filing Date: 5 October 1999

Butanamide, 4-[(aminoiminomethyl)amino]-N-[5-[[2,5-dihydro-4-(1H-indol-3-yl)-2,5-dioxo-1H-pyrrol-3-yl]amino]pentyl]-, (S)- ;
3-phenyl-4-(diethylamino)-pyrrole-2,5-dione;
3-phenyl-4-(benzylamino)-pyrrole-2,5-dione;
1-methyl-3-phenyl-4-(2-diethylaminoethylamino)-pyrrole-2,5-dione;
1-allyl-3-phenyl-4-(2-dimethylaminoethylamino)-pyrrole-2,5-dione; and;
1,3-diphenyl-4-piperidino-pyrrole-2,5-dione.

17. (Amended) A pharmaceutical composition which comprises a compound of formula (IA)



(IA)

wherein

R is hydrogen, alkyl, aryl, or aralkyl;

R^1 is hydrogen, alkyl, aralkyl, hydroxyalkyl or alkoxyalkyl;

R^2 is substituted or unsubstituted aryl or substituted or unsubstituted heterocyclyl;

R^3 is hydrogen, substituted or unsubstituted alkyl, cycloalkyl, alkoxyalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl or aralkyl wherein the aryl moiety is substituted or unsubstituted; or,

R^1 and R^3 together with the nitrogen to which they are attached form a single or fused, optionally substituted, saturated or unsaturated heterocylic ring;

or a pharmaceutically acceptable derivative thereof, and a pharmaceutically acceptable carrier, with the proviso that formula (IA) does not include the following compounds: [contained in List A.]

3-phenyl-4-(4-methylpiperazino)-pyrrole-2,5-dione;
3-[4-(diphenylmethyl)-1-piperazinyl]-4-(1H-indol-3-yl)-1-methyl-1H-pyrrole-2,5-dione;
3-phenyl-4-(4-phenylpiperazino)-pyrrole-2,5-dione;
1-methyl-3-phenyl-4-(4-phenylpiperazino)-pyrrole-2,5-dione;
1-ethyl-3-phenyl-4-(4-chlorophenylpiperazino)-pyrrole-2,5-dione;
1-allyl-3-phenyl-4-(4-methylpiperazino)-pyrrole-2,5-dione;
3-indol-1-yl-4-(1-methyl-1H-indol-3-yl)-pyrrole-2,5-dione;
1-(1-methyl-2,5-dioxo-4-phenylamino-2,5-dihydro-1H-pyrrol-3-yl)pyridinium chloride;
1-[1-(4-methyl-pentyl)-2,5-dioxo-4-phenylamino-2,5-dihydro-1H-pyrrol-3-yl]pyridinium chloride;
1-(1-dodecyl-2,5-dioxo-4-phenylamino-2,5-dihydro-1H-pyrrol-3-yl)-pyridinium chloride;
3-[2-benzo[b]thien-2-yl-3-[4-(dimethylamino)-2,5-dihydro-2,5-dioxo-1H-pyrrol-3-yl]-1H-indol-1-yl]-carbamimidothioic acid, propyl ester;
3-(dimethylamino)-4-(1H-indol-3-yl)-1-methyl-1H-pyrrole-2,5-dione;

Int'l App. No.: PCT/GB99/03280
Int'l Filing Date: 5 October 1999

3-(1H-indol-3-yl)-1-methyl-4-(phenylamino)-1H-pyrrole-2,5-dione;
3-(1H-indol-3-yl)-1-methyl-4-[[4-(trifluoromethyl)phenyl]amino]-1H-pyrrole-2,5-dione;
3-(1H-indol-3-yl)-1-methyl-4-(methylamino)-1H-pyrrole-2,5-dione;
3-(1H-imidazo[4,5-b]pyridin-1-yl)-4-(1H-indol-3-yl)-1-methyl-1H-pyrrole-2,5-dione;
3-(6-chloro-9H-purin-9-yl)-4-(1H-indol-3-yl)-1-methyl-1H-pyrrole-2,5-dione;
3-(6-amino-9H-purin-9-yl)-4-(1H-indol-3-yl)-1-methyl-1H-pyrrole-2,5-dione;
3-(1H-indol-3-yl)-1-methyl-4-(1H-pyrrolo[2,3-b]pyridin-1-yl)-1H-pyrrole-2,5-dione;
3-(1H-indol-3-yl)-1-methyl-4-(1-piperidinyl)-1H-pyrrole-2,5-dione;
1-acetyl-3-[2,5-dihydro-1-methyl-2,5-dioxo-4-[[4-(trifluoromethyl)phenyl]amino]-1H-pyrrol-3-yl]-1H-indole;
3-(1H-benzimidazol-1-yl)-4-(1H-indol-3-yl)-1-methyl-1H-pyrrole-2,5-dione;
3-(1H-benzotriazol-1-yl)-4-(1H-indol-3-yl)-1-methyl-1H-pyrrole-2,5-dione;
3-(1H-imidazol-1-yl)-4-(1H-indol-3-yl)-1-methyl-1H-pyrrole-2,5-dione;
3-(1H-indol-1-yl)-4-(1H-indol-3-yl)-1-methyl-1H-pyrrole-2,5-dione;
3-(1H-indazol-1-yl)-4-(1H-indol-3-yl)-1-methyl-1H-pyrrole-2,5-dione;
3-[3-[(dimethylamino)methyl]-1H-indol-1-yl]-4-(1H-indol-3-yl)-1-methyl-1H-pyrrole-2,5-dione;
3-(1H-benzimidazol-1-yl)-4-(1H-indol-3-yl)-1H-pyrrole-2,5-dione;
3-(1H-indol-1-yl)-4-(1-methyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione;
3-amino-4-(1H-indol-3-yl)-1H-pyrrole-2,5-dione;
3-amino-4-(5-methoxy-1H-indol-3-yl)-1H-pyrrole-2,5-dione;
1H-Indole-1-carboxylic acid, 3-(4-amino-2,5-dihydro-1-methyl-2,5-dioxo-1H-pyrrol-3-yl)-, 1,1-dimethylethyl ester ;
3-(1H-indol-3-yl)-1-methyl-4-[(phenylmethyl)amino]-1H-pyrrole-2,5-dione;
Glycine, N-[2,5-dihydro-4-(1H-indol-3-yl)-1-methyl-2,5-dioxo-1H-pyrrol-3-yl]-, ethyl ester ;
3-amino-4-(1H-indol-3-yl)-1-methyl-1H-pyrrole-2,5-dione;
3-[[3-[(3-aminopropyl)amino]propyl]amino]-4-(1H-indol-3-yl)-1H-pyrrole-2,5-dione;
[[3-[4-(3-aminopropyl)-1-piperazinyl]propyl]amino]-4-(1H-indol-3-yl)-1H-pyrrole-2,5-dione;
3-(1H-indol-3-yl)-4-[[3-(4-methyl-1-piperazinyl)propyl]amino]-1H-pyrrole-2,5-dione ;
1-[3-[(3-aminopropyl)amino]propyl]-3-[[3-[(3-aminopropyl)amino]propyl]amino]-4-(1H-indol-3-yl)-1H-pyrrole-2,5-dione;
1-[3-[4-(3-aminopropyl)-1-piperazinyl]propyl]-3-[[3-[4-(3-aminopropyl)-1-piperazinyl]propyl]amino]-4-(1H-indol-3-yl)-1H-pyrrole-2,5-dione;
3-(1H-indol-3-yl)-1-[3-(4-methyl-1-piperazinyl)propyl]-4-[[3-(4-methyl-1-piperazinyl)propyl]amino]-1H-pyrrole-2,5-dione;
3,3'-[iminobis(3,1-propanediylimino)]bis[4-(1H-indol-3-yl)-1H-pyrrole-2,5-dione;
3,3'-[1,4-piperazinediylbis(3,1-propanediylimino)]bis[4-(1H-indol-3-yl)-1H-pyrrole-2,5-dione;
3-[(5-aminopentyl)amino]-4-(1H-indol-3-yl)-1H-pyrrole-2,5-dione;
3-[[5-[(2-aminoethyl)amino]pentyl]amino]-4-(1H-indol-3-yl)-1H-pyrrole-2,5-dione;
3-[(2-aminoethyl)amino]-4-(1H-indol-3-yl)-1H-pyrrole-2,5-dione ;
3-[(6-aminohexyl)amino]-4-(1H-indol-3-yl)-1H-pyrrole-2,5-dione ;
3-[(7-aminoheptyl)amino]-4-(1H-indol-3-yl)-1H-pyrrole-2,5-dione;
3-[[2-[(2-aminoethyl)amino]ethyl]amino]-4-(1H-indol-3-yl)-1H-pyrrole-2,5-dione;

Int'l App. No.: PCT/GB99/03280
Int'l Filing Date: 5 October 1999

Benzenepropanamide, .alpha.-amino-N-[5-[[2,5-dihydro-4-(1H-indol-3-yl)-2,5- dioxo-1H-pyrrol-3-yl]amino]pentyl]-, (S)- ;
Pentanoic acid, 4-amino-5-[[5-[[2,5-dihydro-4-(1H-indol-3-yl)-2,5-dioxo-1H-pyrrol-3-yl]amino]pentyl]amino]-5-oxo-, (S)- ;
Pentanamide, 2-amino-5-[(aminoiminomethyl)amino]-N-[2-[[5-[[2,5-dihydro-4-(1H-indol-3-yl)-2,5-dioxo-1H-pyrrol-3-yl]amino]pentyl]amino]ethyl]-, (S)-;
Benzenepropanamide, .alpha.-amino-N-[2-[[5-[[2,5-dihydro-4-(1H-indol-3-yl)-2,5-dioxo-1H-pyrrol-3-yl]amino]pentyl]amino]ethyl]-, (S)- ;
Butanamide, 4-[(aminoiminomethyl)amino]-N-[5-[[2,5-dihydro-4-(1H-indol-3-yl)-2,5-dioxo-1H-pyrrol-3-yl]amino]pentyl]-, (S)- ;
3-phenyl-4-(diethylamino)-pyrrole-2,5-dione;
3-phenyl-4-(benzylamino)-pyrrole-2,5-dione;
1-methyl-3-phenyl-4-(2-diethylaminoethylamino)-pyrrole-2,5-dione;
1-allyl-3-phenyl-4-(2-dimethylaminoethylamino)-pyrrole-2,5-dione; and;
1,3-diphenyl-4-piperidino-pyrrole-2,5-dione.